NewLink Genetics Presents Data at the AACR 2014 Annual Meeting
NewLink Genetics Corporation, a biopharmaceutical company focused on discovering, developing and commercialising novel immunotherapeutics to improve treatment options for patients with cancer, presented preclinical data related to the immunostimulatory and anti-tumour effects of its two clinical-stage checkpoint inhibitors targeting the IDO pathway, indoximod and, in combination with anti-PD-1/PD-L antibodies. The data was presented in a poster session at the (AACR) 2014 Annual Meeting. In addition, new compounds that mediate TDO (tryptophan-2,3-dioxygenase) activity were presented.
"Key immune checkpoints such as IDO and PD-1 are interrelated and as a result, combinatorial therapeutic interventions may prove more effective than single agents," commented Dr, Chairman and Chief Executive Officer of NewLink. "These data demonstrate that combining multiple immunotherapies and in this case multiple checkpoint inhibitors that target the IDO pathway and PD1/PDL, is effective in reducing local tumour-mediated immunosuppression and providing potential for enhanced anti-tumour activity. In addition, we are exploring the role of TDO, an enzyme functionally and structurally related to IDO, and are beginning to develop TDO inhibitors as potential new anti-cancer compounds that function on their own and in combination with IDO inhibitors."
In a poster presentation entitled "Synergistic antitumour effects of combinatorial immune checkpoint inhibition with anti-PD-1/PD-L antibodies and the IDO pathway inhibitors and indoximod in the context of active immunotherapy," NewLink researchers and collaborators at presented preclinical data demonstrating that combining IDO pathway inhibitors with agents targeting immune checkpoints provided enhanced anti-tumor effect compared to either agent alone in mouse models of established tumours.
• Demonstrated synergistic effects of combining , indoximod and anti-PD-1/PD-L1/PD-L2 antibodies to block both the IDO and PD pathways resulting in enhanced anti-tumor effects compared to blocking each pathway independently. This synergy was demonstrated in the context of established tumors treated with otherwise ineffective chemo-immunotherapy regimens.
In a second poster presentation entitled "Novel specific- and dual- tryptophan-2,3-dioxygenase (TDO) and indoleamine-2,3-dioxygenase (IDO) inhibitors for tumor immunotherapy," NewLink researchers presented preclinical data demonstrating novel TDO-specific, IDO-specific and TDO and IDO dual inhibitors as potential new anti-cancer compounds that could function individually or in combinations to control TDO and/or IDO activity.
• Discovered a novel class of compounds that show potent and selective TDO inhibition with 10-200-fold increased potency, as well as compounds that show potent IDO-specific inhibition and dual inhibition of TDO and IDO.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance